Table 7.
Prevalence and prognostic relevance of circulating and disseminated tumor cells at time of diagnosis in patients with ovarian, fallopian tube and peritoneal cancer
| Study | Tumor entity | Target cells / Assay | Positivity rate | Prognostic relevance |
|---|---|---|---|---|
| Our study | Primary and relapsed ovarian, fallopian tube and peritoneal cancer |
CTCs CellSearch |
26% (17% in primary, 25% in relapsed cancer) | OS, PFSa,b |
| Fehm, Banys et al. 2013 [6] | Primary ovarian cancer |
DTCs ICC |
27% | OS, PFSb |
| Poveda et al. 2011 [7] | Relapsed ovarian cancer |
CTCs CellSearch |
14% (defined as ≥ 2 CTCs per 10 ml blood) | OS, PFS |
| Banys et al. [5]c | Primary ovarian cancer |
DTCs ICC |
25% | DFS |
| Zhang et al. [22] | Primary ovarian cancer |
CTCs Immunobeads, Multiplex-RT-PCR |
90% | OS shorter in patients with EpCAM-positive CTCs |
| Braun et al. [12]c | Primary ovarian cancer |
DTCs ICC |
30% | DFS, DDFSb, OS |
| Marth et al. 2002 [10] | Primary ovarian cancer |
CTCs Immunobeads |
12% | n.s |
|
DTCs Immunobeads |
21% | n.s | ||
| Schindlbeck et al. [11] | Primary ovarian cancer |
DTCs ICC |
23% | DDFS |
| Aktas et al. 2011 [9] | Primary ovarian cancer |
CTCs Multiplex-RT-PCR (AdnaTest) |
19% | OS |
|
DTCs ICC |
35% | n.s | ||
| Chebouti et al. [13] | Primary ovarian cancer |
DTCs ICC |
42% | OS |
| Fan et al. [18] | Primary ovarian cancer |
CTCs Immunofluorescence and cell invasion assay |
61% | DFS |
| Sehouli et al. [19] | Primary ovarian cancer |
CTCs ICC |
n.a | n.s |
CTCs circulating tumor cells, DDFS distant disease-free survival, DFS disease-free survival, DTCs disseminated tumor cells, ICC immunocytochemistry, OS overall survival, n.s. not significant, PFS progression-free survival
aEntire cohort, statistical significance in subgroups not reached
bMultivariate analysis
cTthese cohorts were completely or partially included in the pooled analysis [6]